Q-omics provides the consensus-scored MIR6499 profile across patient tissues and cancer cell-line models. MIR6499 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR6499 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR6499 RNA expression shows 6,026 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, LUSC, and ESCA as cancer lineages where MIR6499 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6499 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6499 survival associations across molecular data types. MIR6499 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6499 RNA expression–survival associations across cancer types. High MIR6499 expression shows unfavorable associations in MESO, SKCM, UCEC, OV, CESC and LUAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR6499 RNA expression.
This table summarizes MIR6499 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6499. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6499 shows higher tumor expression in LUSC. The LUSC box plot shows higher MIR6499 RNA expression in tumor versus normal tissue (log2 FC = +0.360, t-test p < 0.001).
This table shows molecular features associated with MIR6499 in patient tissues and cancer cell lines. In patient samples, MIR6499 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
